Compliance with results reporting at ClinicalTrials.gov.

BACKGROUND The Food and Drug Administration Amendments Act (FDAAA) mandates timely reporting of results of applicable clinical trials to ClinicalTrials.gov. We characterized the proportion of applicable clinical trials with publicly available results and determined independent factors associated with the reporting of results. METHODS Using an algorithm based on input from the National Library of Medicine, we identified trials that were likely to be subject to FDAAA provisions (highly likely applicable clinical trials, or HLACTs) from 2008 through 2013. We determined the proportion of HLACTs that reported results within the 12-month interval mandated by the FDAAA or at any time during the 5-year study period. We used regression models to examine characteristics associated with reporting at 12 months and throughout the 5-year study period. RESULTS From all the trials at ClinicalTrials.gov, we identified 13,327 HLACTs that were terminated or completed from January 1, 2008, through August 31, 2012. Of these trials, 77.4% were classified as drug trials. A total of 36.9% of the trials were phase 2 studies, and 23.4% were phase 3 studies; 65.6% were funded by industry. Only 13.4% of trials reported summary results within 12 months after trial completion, whereas 38.3% reported results at any time up to September 27, 2013. Timely reporting was independently associated with factors such as FDA oversight, a later trial phase, and industry funding. A sample review suggested that 45% of industry-funded trials were not required to report results, as compared with 6% of trials funded by the National Institutes of Health (NIH) and 9% of trials that were funded by other government or academic institutions. CONCLUSIONS Despite ethical and legal obligations to disclose findings promptly, most HLACTs did not report results to ClinicalTrials.gov in a timely fashion during the study period. Industry-funded trials adhered to legal obligations more often than did trials funded by the NIH or other government or academic institutions. (Funded by the Clinical Trials Transformation Initiative and the NIH.).

[1]  Yuko Kawasumi,et al.  Despite law, fewer than one in eight completed studies of drugs and biologics are reported on time on ClinicalTrials.gov. , 2011, Health affairs.

[2]  A. Smyth,et al.  Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study , 2012, BMJ : British Medical Journal.

[3]  Christopher J. Gill,et al.  How Frequently Do the Results from Completed US Clinical Trials Enter the Public Domain? - A Statistical Analysis of the ClinicalTrials.gov Database , 2014, PloS one.

[4]  C. Grady,et al.  What makes clinical research ethical? , 2000, JAMA.

[5]  J. Feczko.  Clinical trials report card. , 2006, The New England journal of medicine.

[6]  Aaron S Kesselheim,et al.  Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. , 2007, Health affairs.

[7]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[8]  Nicholas C. Ide,et al.  The ClinicalTrials.gov results database--update and key issues. , 2011, The New England journal of medicine.

[9]  P. Ravaud,et al.  Public availability of results of trials assessing cancer drugs in the United States. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Ricardo Pietrobon,et al.  The Database for Aggregate Analysis of ClinicalTrials.gov (AACT) and Subsequent Regrouping by Clinical Specialty , 2012, PloS one.

[11]  C. Gill.  How often do US-based human subjects research studies register on time, and how often do they post their results? A statistical analysis of the Clinicaltrials.gov database , 2012, BMJ Open.

[12]  F. Miller,et al.  Disclosing individual results of clinical research: implications of respect for participants. , 2005, JAMA.

[13]  B. Kuehn,et al.  Few studies reporting results at US government clinical trials site. , 2012, JAMA.

[14]  Ana Marusic,et al.  Clinical Trial Registration Looking Back and Moving Ahead , 2007, Annals of Internal Medicine.

[15]  R. Califf.  A new look at an old therapy. , 2012, JAMA.

[16]  Robert M Califf,et al.  Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. , 2012, JAMA.

[17]  R. Rosenthal,et al.  Selective publication of antidepressant trials and its influence on apparent efficacy. , 2008, The New England journal of medicine.